Press Release - Company Data

OncoGenex Pharmaceuticals Announces Appointment of John A. Bencich as Vice President and Chief Financial Officer
Posted 2014-08-07 00:06NAI Editing
today announced the appointment of John A. Bencich as Vice President and Chief Financial Officer (CFO).

OncoGenex Announces Target Number of Events Reached in Phase 3 SYNERGY Trial of Custirsen in Metastatic Castrate-Resistant Prostate Cancer
Posted 2014-02-10 23:33NAI Editing
today announced that the pre-specified number of events required for final analysis of the Phase 3 SYNERGY trial has been reached.

OncoGenex Announces Update on Phase 3 SYNERGY Trial Evaluating Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer
Posted 2013-11-18 23:34NAI Editing
today announced that the SYNERGY trial is continuing as planned per the recommendation of the Independent Data Monitoring Committee (IDMC).

OncoGenex Announces that the Rainier™ Clinical Trial Evaluating Apatorsen (OGX-427) in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic Cancer is Now Open for Enrollment
Posted 2013-08-26 23:33NAI Editing
today announced initiation of the Rainier™ clinical trial, an investigator-sponsored, randomized, placebo-controlled Phase 2 trial evaluating apatorsen (OGX-427) in combination with ABRAXANE® (paclita

OncoGenex Announces Completion of Patient Enrollment in the Borealis-1™ Trial of OGX-427 in Metastatic Bladder Cancer
Posted 2013-07-15 23:33NAI Editing
today announced that enrollment has been completed in Borealis-1™, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin

OncoGenex Announces Plans for the Initiation of the Cedar™ Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in Advanced Squamous Cell Lung Cancer
Posted 2013-05-22 23:32NAI Editing
today announced plans for the initiation of the Cedar™ clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced

OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
Posted 2013-05-02 07:17NAI Editing
today provided an overview of clinical development activities for its two product candidates, custirsen and OGX-427, and announced first quarter 2013 financial results.

OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic Cancer
Posted 2013-05-01 00:33NAI Editing
today announced plans for the initiation of the Rainier™ trial, an investigator-sponsored, randomized, placebo-controlled Phase 2 trial evaluating OGX-427 in combination with ABRAXANE® (paclitaxel pro

OncoGenex Announces that the Borealis-2™ Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is now Open for Enrollment
Posted 2013-04-30 00:35NAI Editing
today announced initiation of the Borealis-2™ clinical trial, an investigator-sponsored, randomized Phase 2 trial evaluating OGX-427 in combination with docetaxel in patients with advanced or metastat

OncoGenex Announces Plans for the Initiation of the Spruce™ Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer
Posted 2013-04-11 00:59NAI Editing
today announced plans for the initiation of the Spruce clinical trial, an investigator-sponsored, randomized, double-blind, placebo-controlled Phase 2 study evaluating OGX-427 in patients with previou